ARV-393 is an investigational orally bioavailable PROteolysis TArgeting Chimera (PROTAC) designed to degrade B-cell lymphoma 6 protein (BCL6), a transcriptional repressor and major driver of B ...

Explore OMA/AMO’s ‘Diagrams’ at the Prada Foundation in Venice At OMA in the 1980s, Rem Koolhaas and his early colleagues, such as Elia Zenghelis, incorporated the diagram into the wealth of drawing ...

The Close the Gap campaign is aimed at urging those defaulting on ARV treatment to return.

Arvinas, Inc. announced promising preclinical results for ARV-393, a targeted protein degrader aimed at treating non-Hodgkin lymphoma, particularly high grade B-cell lymphomas. Data showed that ...

Arvinas, Inc, a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, announced that new preclinical combination data for ARV-393 will be ...

Health Cabinet Secretary Deborah Barasa has reaffirmed Kenya's dedication to providing uninterrupted care for individuals living with HIV, despite recent challenges stemming from a freeze in ...

Despite government reassurances, health experts have serious concerns about the long-term implications of the withdrawal of funding for HIV/Aids treatment programmes.

IN a recent statement, the Health and Child Care minister revealed that Zimbabwe has enough antiretroviral (ARV) drugs to last for the next six months.

Create stunning diagrams in seconds with Excalidraw’s AI-powered features. Customize, collaborate, and export with ease.

A look at the curious history of Venn diagrams and the way they blend logic with geometry ...

The National Department of Health must finalise its planning to ensure all eligible individuals in South Africa receive a six-month supply of ARVs, with an implementation plan and timelines to be ...